Mal-PEG4-VC-PAB-DMEA-PNU-159682 |
| Catalog No.GC63503 |
Mal-PEG4-VC-PAB-DMEA-PNU-159682, un conjugué médicament-lieur pour l'ADC, est constitué du lieur ADC Mal-PEG4-VC-PAB et d'une puissante cytotoxine ADC DMEA-PNU-159682. Le DMEA-PNU-159682 comprend des métabolites de la némorubicine (MMDX) provenant de microsomes hépatiques et de la cytotoxine ADC PNU-159682.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2259318-52-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Mal-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for ADC, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682[1].
[1]. John Flygare, et al. Anthracycline disulfide intermediates, antibody-drug conjugates and methods. WO2016040825A1
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *